title: [Inhaled antibiotic therapy in bronchiectasis?].
abstract: Antimicrobial therapy is an important aspect of disease management for patients with bronchiectasis. Delivery of an inhaled antibiotic is an appealing alternative to oral or intravenous administration because the antibiotic is delivered in high concentrations directly to the site of infection, eliminating the need for high systemic concentrations and reducing the risk of systemic toxicity. In recent controlled studies these potential benefits have been assessed in patients with bronchiectasis who became colonized by P. aeruginosa and the results support the use of nebulized antibiotics. In up to one-third of patients P. aeruginosa was eradicated from their sputum by inhaled antibiotic therapy and up to 62 % of patients showed improved medical condition. The further development of new aerosol devices supported by clinical testing will allow effective management of patients with bronchiectasis by an inhalation therapy that minimizes time constraints and drug loss which may improve health status and quality of life.
authors.affiliation: Asklepios Fachklinik München-Gauting, Zentrum für Pneumologie und Thoraxchirurgie, Gauting. m.kohlhaeufl@asklepios.com
authors.forename: M
authors.initials: M
authors.lastname: Kohlhäufl
authors.forename: G
authors.initials: G
authors.lastname: Scheuch
authors.forename: K
authors.initials: K
authors.lastname: Häussinger
mesh_terms: D000280:Administration, Inhalation; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001987:Bronchiectasis / Q000188:drug therapy*; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents